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Background: Epidemiologic evidence shows that obesity is associated with a greater 
risk of aggressive prostate cancer (PCa) and PCa-specific mortality and this is observed 
mainly in men with the TMPRSS2-ERG gene fusion. Obesity is often associated with 
comorbid conditions such as type 2 diabetes and hyperglycemia: we investigated 
whether some of the exposures associated with disturbed metabolism can also affect 
the frequency of this gene fusion.
Methods: Fusion was induced in LNCaP PCa cells in normal or high levels of glucose, 
with or without insulin-like growth factor binding protein-2 (IGFBP-2) silenced or the 
presence of insulin-like growth factor-1 (IGF-I), insulin, or epidermal growth factor (EGF). 
RNA was extracted for analysis by nested PCR. Abundance of IGFBP-2, γH2AX, DNA-
dependent protein kinase catalytic subunit (DNAPKcs), and β-actin were analyzed by 
Western immunoblotting.
results: Our data suggest that hyperglycemia-induced IGFBP-2 increased the fre-
quency of the gene fusion that was accompanied by decreased levels of DNAPKcs 
implying that they were mediated by alterations in the rate of repair of double-strand 
breaks. In contrast insulin, IGF-I and EGF all decreased gene fusion events.
conclusion: These novel observations may represent a further mechanism by which 
obesity can exert an effect aggravating PCa progression.
Keywords: prostate cancer, insulin-like growth factor-binding protein-2, TMPrss2-erg, hyperglycemia, type ii 
diabetes
inTrODUcTiOn
The TMPRSS2-ERG fusion oncogene is thought to be important during tumor progression and 
development as it is found in approximately half of all prostate cancer (PCa) biopsies and also in 
metastases (1–3).
Joining of the 5′-untranslated region of TMPRSS2 with the oncogenic ETS transcription factor, 
ERG culminates in the TMPRSS2-ERG gene fusion. TMPRSS2 possesses androgen-responsive ele-
ments and so in response to androgens TMPRSS2 drives ERG overexpression. Antiandrogens can 
decrease ERG in patients carrying TMPRSS2-ERG through its ability to reduce the levels of androgen. 
In contrast, for patients whose PCa progresses and becomes resistant to antihormone therapy, the 
fusion oncogeneTMPRSS2-ERG can be reactivated and could thus contribute to tumor progression (4).
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We are currently facing a global obesity epidemic that has been 
associated with a negative impact on PCa. There is strong epide-
miologic evidence that obesity is associated with a greater risk 
of aggressive PCa and increased PCa-specific mortality (5–7). 
Furthermore, the negative impact of obesity on PCa prognosis 
has mainly been observed in men with the TMPRSS2-ERG gene 
fusion (8) implying an interaction.
Obesity is often associated with comorbid conditions such as 
insulin resistance, hyperglycemia, and type 2 diabetes. We have 
shown previously that hyperglycemia-induced chemoresistance 
in PCa cells and that this was mediated by an epigenetic upregula-
tion of insulin-like growth factor binding protein-2 (IGFBP-2) (9). 
IGFBP-2 is one of the six high-affinity IGF-binding proteins, which 
bind to IGFs, acting as a carrier and protecting them from clear-
ance, increasing their half-lives, and modulating their availability 
and activity. These IGFBPs, including IGFBP-2 can also regulate 
cell function independently of the insulin-like growth factor-1 
(IGF-I) receptor (10, 11). IGFBP-2 is considered to be a key player 
in PCa progression (12) with IGFBP-2 levels being raised in the 
serum and in the tumors of patients with PCa (13, 14).
PTEN is a phosphoprotein that exhibits both protein- and 
lipid-phosphatase activity that inhibits the phosphatidylinositol 
3-kinase/Akt and mitogen-activated protein kinase signaling 
pathways (15–17), thereby acting in an opposite manner to growth 
factors, which promote cell growth and survival. We identified that 
IGFBP-2 inhibited PTEN function in PCa cells by increasing its 
phosphorylation (18) and global expression profiling indicated that 
IGFBP-2 was the most important biomarker to indicate the status 
of PTEN in tumors (19). When PTEN is silenced, mice develop 
high grade prostatic intraepithelial neoplasia, but do not progress 
to develop cancer (20). 93% of ERG rearrangement positive sam-
ples showed either absent or reduced PTEN (21) and tumors lack-
ing functional PTEN express higher levels of ERG rearrangement 
(22). IGFBP-2 has also been shown to translocate to the nucleus in 
neuroblastoma cells, via its nuclear localization sequence, where 
it directly associates with DNA and functions as a transcription 
factor, modulating specific tumorigenic genes (23, 24).
The high frequency of the TMPRSS2-ERG gene fusion in 
PCa is not due to random translocations but is promoted by the 
androgen receptor inducing changes in chromosomal architec-
ture leading to the proximity of the TMPRSS2 and ERG genes that 
are then fused following double-strand breaks (DSB) and repair 
via the non-homologous end joining (NHEJ) pathway (25). There 
have been several studies examining the effects of androgen 
exposure on the formation of fusion products (26, 27), but little 
work examining potential effects of other exposures. In this study, 
we examined the effect of some of the exposures associated with 
disturbed metabolism on TMPRSS2-ERG gene fusion, in particu-
lar, hyperglycemia and the potential role of IGFBP-2 in the latter.
MaTerials anD MeThODs
Materials
All chemicals, unless otherwise stated, were purchased from 
Sigma (Poole, UK). LNCaP cells were bought from ATCC and 
cultured as described previously (9). All cell lines tested negative 
for mycoplasma.
Fusion induction
LNCaP cells were seeded in 6-well plates in DMEM growth media 
(Basel, Switzerland, GM: 5 mM glucose) with or without IGFBP-2 
silenced for 24 h, serum starved for 24 h in the presence of aphidi-
colin (2 µg/ml) in DMEM and HAM’S Nutrient Mix F12 media 
containing charcoal-stripped serum (Invitrogen, Paisley, UK, 
SFM: 25 mM) and then dosed with dihydrotestosterone (DHT:0.1 
μM) in the presence or absence of IGF-I, Gropep, Adelaide, SA, 
Australia (100  ng/ml), insulin, Novo Nordisk, West Sussex, 
UK (100  ng/ml), or epidermal growth factor (EGF), Merck, 
Hertfordshire, UK (20 ng/ml) for 2 h in fresh charcoal-stripped 
serum based media followed by the addition of etoposide (60 µM) 
for 1 h. We confirmed that dosing with etoposide at this dose for 
1 h did not induce any consequent cell death (data not shown). 
Before assessing whether IGF-I, insulin, or EGF affected the rate 
of fusion in LNCaP cells, we initially assessed how responsive 
these cells were to the factors in relation to DNA proliferation. 
On performing dose responses, we found that 20 ng/ml EGF and 
100 ng/ml IGF-I and insulin gave the greatest response in terms 
of growth and so used these doses for the fusion experiments. 
Optimum doses of DHT and etoposide that were used were 
selected from previous dose response curves (data not shown). 
Cells were incubated in fresh charcoal-stripped serum based 
media for a further 24  h prior to the extraction of RNA using 
Trizol reagent from Invitrogen (Carlsbad, CA, USA) according to 
manufacturer’s instructions and conversion to cDNA using a kit 
from Invitrogen (SuperScript III First-Strand Synthesis System). 
IGFBP-2 was silenced, parallel to non-silencing controls, using 
siRNA (100  nM) and a second siRNA for IGFBP-2 was also 
used to exclude off-target responses: sequences of siRNAs and 
methodology described previously (9, 28).
Quantitative nested Pcr
Each tube of cDNA was separated into 10 × 2 µl aliquots. These 
were used in 10 separate nested PCR reactions amplified using 
primer pair 1 (TMPRSS2 forward CAGGAGGCGGAGGCGGA: 
ERG reverse GGCGTTGTAGCTGGGGGTGAG). 2  μl of this 
PCR product was then taken and used to initiate the second 
round of PCR amplified using primer pair 2 (TMPRSS2 for-
ward GGAGCGCCGCCTGGAG: ERG reverse CCATATTC 
TTTCACCGCCCACTCC) in a further 10 reactions as described 
previously (29). Each PCR product was run on a 1.7% agarose gel 
and the total number of PCR products from these 10 reactions 
counted and compared. This process was repeated for each treat-
ment in triplicate.
Western immunoblotting
Insulin-like growth factor binding protein-2, γH2AX, DNA-
dependent protein kinase (DNAPK)cs, and β-actin were analyzed 
by Western immunoblotting as described previously (9).
statistical analysis
Data were analyzed with SPSS 12.0.1 for Windows using 
one-way ANOVA followed by least significant difference 
post hoc test. A statistically significant difference was present 
at *p < 0.05.
FigUre 1 | Continued
3
Holly et al. IGFBP-2 Promotes TMPRSS2-ERG Fusion
Frontiers in Endocrinology | www.frontiersin.org November 2017 | Volume 8 | Article 305
FigUre 1 | Effects of hyperglycemia on TMPRSS2:ERG fusion induction in LNCaP prostate cancer cells. LNCaP cells were seeded (0.7 × 106 cells/well) in 6-well 
plates in normal glucose-containing DMEM growth media (GM: 5 mM glucose) for 24 h, serum starved for 24 h in the presence of aphidicolin (2 µg/ml) in either normal 
or high glucose-containing DMEM and HAM’S Nutrient Mix F12 media containing charcoal-stripped serum (SFM: 25 mM), and then dosed with DHT (0.1 µM) for 2 h 
in fresh charcoal-stripped serum based media followed by the addition of etoposide (60 µM) for 1 h. Cells were incubated in fresh charcoal-stripped serum based 
media for a further 24 h. LNCaP cells were also seeded (0.7 × 106 cells/well) in high glucose-containing GM and insulin-like growth factor binding protein-2 (IGFBP-2) 
was silenced parallel to non-silencing controls using siRNA (100 nM). After 16 h cells were serum starved in high glucose-containing SFM as above for a further 24 h 
and treated with 0.1 µM DHT for 2 h and 60 µM etoposide for a further 1 h. Cells were incubated in fresh SFM for a further 24 h. Cells were extracted in trizol for 
performing nested PCR. (a,c) Illustrate three repeats of the gels showing PCR products (each indicated by an arrow) and number of PCR products in top corner of 
each blot (B,D) is the quantification of the PCR products. Insert to (D) is a representative western immunoblot for IGFBP-2 and β-actin (NS, non-silencing siRNA).
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FigUre 2 | Continued  
Effects of insulin, epidermal growth factor (EGF), and insulin-like growth 
factor-1 (IGF-I) on TMPRSS2:ERG fusion induction in LNCaP prostate cancer 
cells. LNCaP cells (0.7 × 106 cells/well) were seeded in 6-well plates and 
serum starved as described in figure legend 1 for a further 24 h and treated 
with 0.1 µM DHT for 2 h in the presence or absence of IGF-I (100 ng/ml), 
insulin (100 ng/ml), or EGF (20 ng/ml) followed by 60 µM etoposide for a 
further hour. A final 24 h incubation with fresh SFM was followed by RNA 
extraction in Trizol for analysis by nested PCR. (a–l) Illustrates three repeats of 
the gels showing PCR products with the number of PCR products in brackets 
after the title of each blot and (M) is the quantification of the PCR products.
FigUre 2 | Continued
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resUlTs
effect of glucose on the number of 
TMPrss2:erg Fusion Products: a role 
for igFBP-2
Figures 1A,B show that the average number of TMPRSS2:ERG 
fusion products was higher in 25 mM glucose (6.3) compared to 
5 mM glucose (3), with the average rate over 2.1-fold higher at 
25 mM than at 5 mM (p < 0.01). As we have shown previously, 
using ELISA and western blotting that high glucose increases 
the abundance of IGFBP-2 compared with levels observed in 
5 mM glucose by 1.8-fold (p < 0.01) (9), these data suggested 
that the glucose-induced increase in IGFBP-2 may be related 
to the increase in TMPRSS2:ERG fusion products. Therefore, 
to examine this more specifically, we silenced IGFBP-2 using 
siRNA in high glucose conditions and observed a significant 
decrease in TMPRSS2:ERG fusion products (p < 0.05): effec-
tive silencing of IGFBP-2 is indicated by a western blot 
(Figures 1C,D).
effect of insulin, egF, and igF-i on the 
number of TMPrss2-erg Fusion 
Products
The average rate of fusion induction was decreased 3.5-fold 
by insulin (that does not bind IGFBPs) (Figures  2A,B,E,F,I,J) 
and over 2.5-fold by IGF-I (Figures  2A,D,E,H,I,L). We also 
observed a 3.5-fold decrease by an alternative growth factor, EGF 
(Figures 2A,C,E,G,I,K). While the decrease in fusion induction 
with insulin and EGF treatment were statistically significant 
(p < 0.05), the decrease observed in the presence of IGF-I was 
not statistically significant (Figure 2M).
effects of silencing igFBP-2 or adding 
igF-i on levels of γh2aX and Dna-
Dependent Protein Kinase catalytic 
subunit (DnaPKcs)
Figure 3A shows an increase in γH2AX after etoposide treatment, 
corresponding to a dramatic increase in DSBs. At 3, 4, and 5 h the 
bands depicting the levels of γH2AX were substantially higher 
in cells in which IGFBP-2 had been knocked down compared to 
non-silencing controls. A decrease in the levels of DNAPKcs after 
IGFBP-2 knockdown was observed at 3, 4, and 5 h after etoposide 
and DHT dosing compared to non-silencing treated cells. This 
6Holly et al. IGFBP-2 Promotes TMPRSS2-ERG Fusion
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FigUre 3 | Continued
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FigUre 3 | Continued  
Effects of silencing insulin-like growth factor binding protein-2 (IGFBP-2) or adding insulin-like growth factor-1 (IGF-I) on levels of γH2AX and DNA-dependent protein 
kinase catalytic subunit (DNAPKcs) in LNCaP prostate cancer cells. Cells were seeded and dosed as in the legend for Figure 1 and following etoposide treatment 
were incubated in fresh SFM and lysed every 1 h from 3 h in SFM. (a) Shows a representative blot of levels of IGFBP-2, γH2AX, DNAPKcs, and β-actin analyzed by 
Western immunoblotting as described previously (9). (B) Densitometry of the western blot shown in (a) indicating levels of γH2AX, DNAPKcs normalized to β-actin 
levels relative to the non-silencing untreated control. Following etoposide, treatment cells were lysed after 4 h in fresh SFM and (c) shows a representative western 
blot that has been repeated three times showing of levels of IGFBP-2, γH2AX, DNAPKcs normalized to tubulin levels. [(c)i,ii,iii] densitometry showing the mean 
changes of three experiments showing levels ofγH2AX and DNAPKcs, respectively, normalized to tubulin levels relative to the non-silencing untreated control. Cells 
were seeded and dosed with IGF-I (100 ng/ml) as in the legend for Figure 2 and following etoposide treatment cells were lysed after 4 h in fresh SFM. (D) Shows a 
representative western blot that has been repeated three times showing of levels of γH2AX and DNAPKcs normalized to tubulin levels and [(D)i,ii] show densitometry 
of the mean changes of three experiments indicating levels of DNAPKcs and γH2AX, respectively, normalized to tubulin levels.
was verified by densitometry shown in Figure 3B. We repeated the 
experiment at the 4 h time point to confirm that levels of γH2AX 
were significantly increased (p = 0.003) and those of DNAPKcs 
were significantly (p = 0.011) decreased with IGFBP-2 silenced 
(p = 0.009) (Figure 3Ci,ii,iii). Figure 3Di,ii show that DHT and 
etoposide treatment alone increased levels of DNAPKcs and of 
γH2AX (p =  0.01 and p <  0.01, respectively). Although IGF-I 
alone increased DNAPKcs (p < 0.05), in the presence of DHT and 
etoposide, IGF-I acted in an opposite way and reduced DNAPKcs 
(p = 0.01). IGF-I, however, had no effect on γH2AX either alone 
or in combination with DHT and etoposide.
DiscUssiOn
Knowing that high glucose increases the abundance of IGFBP-2 
in PCa cells (9), we used this model to assess whether increasing 
levels of glucose altered the number of TMPRSS2-ERG fusion 
products induced by exposure to DHT and etoposide and if this 
was mediated by IGFBP-2. Our data suggest that high glucose 
increases the number of TMPRSS2:ERG fusion products, and this 
was not seen when the accompanying increase in IGFBP-2 was 
prevented, consistent with IGFBP-2 playing a role in this effect. 
It would be interesting to investigate whether other inducers of 
IGFBP-2 also elicit such an effect and indeed whether adding 
exogenous IGFBP-2 to the cells in normo-glycemic conditions 
also increased the number of TMPRSS2-ERG fusion products 
induced by exposure to DHT and etoposide, as this would infer 
a more general role for IGFBP-2. The NHEJ pathway is a process 
that repairs DSB in DNA (30). Silencing components involved in 
the process of NHEJ prevents TMPRSS2:ERG gene fusions (25) 
indicating that NHEJ is a major method for generating fusions. 
DNAPK is a large protein complex that plays an important role in 
NHEJ in DNA-DSB repair and possesses a catalytic subunit called 
DNAPKcs. DNAPK is critical for controlling progression through 
the cell cycle and maintaining genomic stability (31). As well as 
DNAPK being modulated through its interactions with DNA, its 
activity can also be regulated by a variety of other mechanisms, 
including modulation of DNAPKcs. A study in HeLa cells (32) 
concluded that DNAPKcs plays an important role in the regula-
tion of γH2AX phosphorylation in response to DNA damage. 
Phosphorylation of γH2AX is essential to mark the DSB allowing 
the DNA repair machinery to identify its location (33). Our data 
suggest that IGFBP-2 has a role in increasing the rate of repair 
of DSBs by increasing levels of DNAPKcs and this culminates in 
increased TMPRSS2:ERG gene fusion. An effect of IGFBP-2 on 
DNAPK has previously been observed: treatment of astrocytes 
with IGFBP-2 resulted in a direct induction of DNAPKcs (34). 
Additional studies provide further support suggesting a role of 
IGFBP-2 in facilitating DNA repair: in glioblastoma studies, 
IGFBP-2 alters the expression of the following DNA repair genes: 
X-ray repair complementing defective repair 2, cyclin-dependent 
kinase inhibitor 1A, and CDC28 protein kinase 2 (35). In addi-
tion, a large-scale study, also in glioblastomas, showed that both 
the DNA-DSB repair pathway and the homologous recombina-
tion pathway are associated with IGFBP-2 expression, altering a 
broad range of proteins including p53, GADD45, TOP2A, and 
BRCA1 (36). Of all the six similar IGFBPs, IGFBP-2 has most 
frequently been reported to be overexpressed in a range of human 
cancers and only IGFBP-2 has been linked to the DNA-DSB 
repair pathway. It would, however, be interesting to investigate 
whether other IGFBPs could have similar actions. In our model 
showing that adding or silencing any of the other IGFBPs had no 
effect on fusion induction would imply that this was a specific 
effect of IGFBP-2.
It has become increasingly clear that IGFBPs, including 
IGFBP-2, can exert effects that are both dependent and independ-
ent of its interactions with IGFs (11). To investigate if the effects 
of IGFBP-2 in promoting TMPRSS2:ERG gene fusions through 
facilitating DNA repair were dependent on IGF-I, we exposed 
LNCaP cells to IGF-I alone or following treatment with DHT 
and etoposide and compared this to the effects of insulin (that 
does not bind IGFBPs) and EGF (an alternative growth factor). 
The effects of IGF-I on DNAPKcs might suggest the effects of 
IGFBP-2 on DNAPKcs were dependent on binding to IGF-I 
and negating its effect. Further work is required to confirm the 
IGF-dependency of IGFBP-2 in DSB repair and the induction of 
fusion; as we did not observe any effect of IGF-I on γH2AX at this 
time point, although IGF-I induced a reduction in the frequency 
of fusion products, it was not statistically significant. It is possible 
that a potential reduction in fusion products induced by IGF-I 
was not due to an effect on DNA repair but could have been an 
effect on chromosomal architecture. It has been observed that, 
in LNCaP-LN3 cells (a derivative of the LNCaP cells that were 
used in our study), blocking the IGF-I receptor had no effect on 
γH2AX focus formation, suggesting that activation of the IGF-IR 
in this cell line has no effect on DSB repair (37).
In summary, our data suggest that exposure to insulin and 
potentially IGF-I reduced the frequency of formation of fusion 
products whereas both hyperglycemia and IGFBP-2 increased 
the number of TMPRSS2-ERG gene fusions and these factors 
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